RTP801 interacts with the tRNA ligase complex and dysregulates its RNA ligase activity in Alzheimer's disease.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
12 Sep 2024
Historique:
accepted: 27 08 2024
revised: 21 08 2024
received: 10 05 2024
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

RTP801/REDD1 is a stress-responsive protein overexpressed in neurodegenerative diseases such as Alzheimer's disease (AD) that contributes to cognitive deficits and neuroinflammation. Here, we found that RTP801 interacts with HSPC117, DDX1 and CGI-99, three members of the tRNA ligase complex (tRNA-LC), which ligates the excised exons of intron-containing tRNAs and the mRNA exons of the transcription factor XBP1 during the unfolded protein response (UPR). We also found that RTP801 modulates the mRNA ligase activity of the complex in vitro since RTP801 knockdown promoted XBP1 splicing and the expression of its transcriptional target, SEC24D. Conversely, RTP801 overexpression inhibited the splicing of XBP1. Similarly, in human AD postmortem hippocampal samples, where RTP801 is upregulated, we found that XBP1 splicing was dramatically decreased. In the 5xFAD mouse model of AD, silencing RTP801 expression in hippocampal neurons promoted Xbp1 splicing and prevented the accumulation of intron-containing pre-tRNAs. Finally, the tRNA-enriched fraction obtained from 5xFAD mice promoted abnormal dendritic arborization in cultured hippocampal neurons, and RTP801 silencing in the source neurons prevented this phenotype. Altogether, these results show that elevated RTP801 impairs RNA processing in vitro and in vivo in the context of AD and suggest that RTP801 inhibition could be a promising therapeutic approach.

Identifiants

pubmed: 39268577
pii: 7755871
doi: 10.1093/nar/gkae776
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agencia Estatal de Investigación
ID : SAF2017-88812-R
Organisme : ERDF A way of making Europe
ID : PID2020-119386RB-I00
Organisme : European Union NextGenerationEU/PRTR
ID : CNS2022 - 135391
Organisme : Fundación Ramón Areces
ID : CIVP21A7024
Organisme : Spanish Ministry of Science and Innovation
ID : #FPU18/00194
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : #FI-B-00378
Organisme : Michael J. Fox Foundation
ID : MJFF-000858
Organisme : Generalitat de Catalunya
ID : 2021 SGR 01086
Organisme : University of Barcelona
ID : MDM-2017-0729
Organisme : Ministry of Science, Innovation, and Universities
Organisme : CIBERNED
Organisme : Universitat de Barcelona

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

Auteurs

Genís Campoy-Campos (G)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Julia Solana-Balaguer (J)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Anna Guisado-Corcoll (A)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036 Catalonia, Spain.

Almudena Chicote-González (A)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Pol Garcia-Segura (P)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Leticia Pérez-Sisqués (L)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Adrian Gabriel Torres (AG)

Institut de Recerca Biomèdica (IRB Barcelona), Barcelona 08028, Catalonia, Spain.
Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Catalonia, Spain.

Mercè Canal (M)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Laura Molina-Porcel (L)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona 08036, Catalonia, Spain.
Neurological Tissue Bank, Biobank-Hospital Clínic-FRCB-IDIBAPS, Barcelona 08036, Catalonia, Spain.

Joaquín Fernández-Irigoyen (J)

Proteored-ISCIII, Proteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona 31008, Spain.

Enrique Santamaria (E)

Proteored-ISCIII, Proteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona 31008, Spain.

Lluís Ribas de Pouplana (LR)

Institut de Recerca Biomèdica (IRB Barcelona), Barcelona 08028, Catalonia, Spain.
Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Catalonia, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Catalonia, Spain.

Jordi Alberch (J)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036 Catalonia, Spain.
Faculty of Medicine and Health Science, Production and Validation Center of Advanced Therapies (Creatio), Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.

Eulàlia Martí (E)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.

Albert Giralt (A)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036 Catalonia, Spain.
Faculty of Medicine and Health Science, Production and Validation Center of Advanced Therapies (Creatio), Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.

Esther Pérez-Navarro (E)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036 Catalonia, Spain.

Cristina Malagelada (C)

Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28029, Spain.

Classifications MeSH